{"Clinical Trial ID": "NCT02732119", "Intervention": ["INTERVENTION 1:", "- Cohort A", "Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days.", "INTERVENTION 2:", "- Cohort B", "Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally"], "Eligibility": ["Incorporation criteria:", "Adult men and women", "The patient has a confirmed diagnosis of positive estrogen-receptor and/or positive progesterone receptor breast cancer by the local laboratory and HER2-negative breast cancer", "The patient should have a disease measurable by RECIST 1.1 or bone damage in the absence of a measurable disease.", "ECOG Performance Statement 0 - 1", "- Diseases refractory to either, AI, tamoxifen or fulvestrant", "Previously treated on any CDK 4/6 inhibitor.", "The patient has an adequate function of the bone marrow and organs.", "- Exclusion criteria:", "A patient with symptomatic visceral disease or disease burden that renders the patient ineligible for endocrine treatment by the investigator's best judgment.", "The patient received more than one line of chemotherapy for an advanced disease.", "Previous treatment with mTOR or exemestane inhibitors for advanced disease.", "\u2022 Progressed on more than one CDK 4/6 inhibitor", "Unless at least 4 weeks after completion of treatment.", "A clinically significant and uncontrolled heart disease and/or recent heart events."], "Results": ["Performance measures:", "Participants with a limiting dose of toxicity by cycle 1 duration (28 days) - in Phase I", "A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value that has a reasonably possible relationship with the study drugs and is unrelated to the disease, disease progression, intercurrent disease or concomitant drugs that occur within the first 28 days of treatment (cycle 1) and that meet one of the criteria defined in the protocol.", "Timeline: Baseline up to 28 days", "Results 1:", "Title of the arm/group: Cohort A", "Description of the arm/group: Ribociclib (250 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally for 28 days.", "Total number of participants analysed: 8", "Type of measure: Number of participants", "Unit of measure: Participants Febrile Neutropenia Grade 3: 1 12.5%", "Neutropenia Grade 4: 0 0.0%", "Thrombocytopenia Grade 4: 0 0.0%", "Grade 4: 1 12.5%", "Diarrhoea Grade 3: 1 12.5%", "Hyperglycaemia Grade 4: 0 0.0%", "Results 2:", "Title of the arm/group: Cohort B", "Description of the arm/group: Ribociclib (300 mg daily), everolimus (2.5 mg daily) and exemestane (25 mg daily) taken orally", "Total number of participants analysed: 10", "Type of measure: Number of participants", "Unit of measure: Participants Febrile Neutropenia Grade 3: 1 10.0%", "Neutropenia Grade 4: 1 10.0 %", "Thrombocytopenia Grade 4: 1 10.0%", "Cardiac Tapponade Grade 4: 0 0.0%", "Diarrhoea Grade 3: 0 0.0%", "Hyperglycaemia Grade 4: 0 0.0%"], "Adverse Events": ["Undesirable Events 1:", "Total: 3/8 (37.50 per cent)", "Anemia 0/8 (0.00 %)", "Febrile neutropenia 1/8 (12.50%)", "Neutropenia 2/8 (25.0%)", "Acute coronary syndrome 0/8 (0.00 %)", "Atrial fibrillation 0/8 (0.00 %)", "Heart failure 0/8 (0.00 %)", "- Cardiac tapponade 1/8 (12.50%)", "Abdominal pain 1/8 (12.50%)", "Diarrhoea 1/8 (12.50 per cent)", "Intestinal occlusion 0/8 (0.00 %)", "- Nausea 0/8 (0.00 %)", "Adverse Events 2:", "Total: 3/10 (30.00 per cent)", "Anemia 0/10 (0.00 %)", "Febrile neutropenia 0/10 (0.00 %)", "Neutropenia 0/10 (0.00 %)", "Acute coronary syndrome 0/10 (0.00 %)", "Atrial fibrillation 0/10 (0.00 %)", "Heart failure 0/10 (0.00 %)", "- Cardiac Tapponade 0/10 (0.00 %)", "Abdominal pain 0/10 (0.00 %)", "Diarrhoea 0/10 (0.00 %)", "Intestinal occlusion 1/10 (10.00%)", "- Nausea 0/10 (0.00 %)"]}